Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $80

Benzinga · 1d ago
Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $67 to $80.